Quartz 4

Nasal Mast Cell Precedent

4 min read

Nasal Mast Cell Precedent

Why Nasal Mast Cells

Nasal mucosa is one of the most accessible mast cell populations in the body. Unlike gut mast cells (endoscopic biopsy required), skin mast cells (punch biopsy), or bronchoalveolar mast cells (bronchoscopy), nasal mast cells sit directly at an accessible epithelial surface.

Mast cell density in nasal mucosa is high — particularly in the lamina propria of the lateral nasal wall and inferior turbinate. This is not incidental: nasal mast cells are sentinels at a major host-environment interface, involved in allergic rhinitis, non-allergic rhinitis, and local inflammatory responses.

Existing Precedent for Nasal MC Harvest

Allergic Rhinitis Research

Nasal mast cells are well-studied in allergic rhinitis. Nasal lavage and brushing protocols to collect cells for ex vivo analysis exist in the research literature. Studies have characterized nasal mast cell phenotype, IgE receptor expression, and mediator release profiles from brushed/lavaged samples.

This means: the basic methodology of collecting nasal cells and studying them ex vivo is not novel. We are applying an existing collection approach to a new assay context.

Nasal Provocation Testing

Controlled allergen challenge directly to nasal mucosa — the allergen is delivered, mediator levels in nasal lavage fluid are measured afterward. This is used in research and specialist clinical settings to confirm specific allergen sensitivity.

The conceptual framework of our assay is essentially a nasal provocation test run in reverse — instead of delivering allergen to cells in the body and measuring what comes out, we collect cells and deliver liberator ex vivo. Same biology, different direction. Avoids systemic provocation entirely.

Cytology Brush Techniques

Nasal cytology brushing (cytobrush) is used clinically to collect cells for eosinophil counts, bacterial cultures, and ciliary function testing. The technique is established, tolerated, and produces sufficient cell yields for analysis in those contexts.

Whether mast cell yield from cytobrush is sufficient for degranulation assay is the open question — mast cells are tissue-resident (not surface epithelium) and may be captured in lower numbers than epithelial cells. This is the primary unknown the feasibility experiment addresses.

Mast Cell Subpopulations

Nasal mast cells are primarily MCT subtype (tryptase-positive, chymase-negative) — the mucosal phenotype. This is distinct from skin mast cells which are predominantly MCTC (tryptase and chymase positive).

Relevance for the assay:

  • Tryptase is present in both subtypes — tryptase-based detection valid for nasal MC
  • MRGPRX2 expression varies by subtype — compound 48/80 and substance P responses may differ between nasal and skin populations
  • Nasal MCT population is well characterized in allergic rhinitis literature — published degranulation profiles exist for reference

Representativeness Question

Do nasal mast cell reactivity scores reflect systemic MCAS reactivity?

Arguments for reasonable correlation:

  • MCAS is a systemic condition — reactivity is a property of the mast cell population broadly, not specific to one tissue site
  • Nasal symptoms are common in MCAS — nasal mast cells are likely part of the reactive population
  • Treatment effects (ketotifen, cromolyn) are systemic — if treatment shifts nasal MC reactivity, it’s shifting the same phenotype seen elsewhere

Arguments for caution:

  • Regional specialization is real — nasal MCT and skin MCTC have different receptor profiles and trigger sensitivities
  • A patient whose primary MCAS manifestation is GI may have different gut vs nasal MC reactivity
  • Nasal activation state may be dominated by local factors (allergen load, infection) not representative of systemic baseline

Practical conclusion: Nasal MC reactivity score is probably a useful proxy for systemic reactivity, particularly for treatment monitoring (did the score shift after ketotifen?) where the absolute value matters less than the delta. Clinical correlation study against confirmed MCAS patients would be needed to validate absolute score interpretation.

What Would Strengthen the Case

  • Comparison of nasal vs skin biopsy MC reactivity in same subjects
  • Correlation of nasal reactivity score with serum tryptase post-reaction events
  • Response curve overlap between nasal MC assay and BAT (basophil activation test) results in same subjects

These are post-feasibility research questions, not blockers for the initial experiment.

Graph View